Chk1 is a key regulator of the S and G2/M checkpoints and is activated following DNA damage by agents such as the topoisomerase I inhibitor camptothecin (CPT). It has been proposed that Chk1 inhibitors used in combination with such a DNA damaging agent to treat tumors would potentiate cytotoxicity and increase the therapeutic index, particularly in tumors lacking functional p53. The aim of this study was to determine whether gene expression analysis could be used to inform lead optimization of a novel series of Chk1 inhibitors. The candidate small-molecule Chk1 inhibitors were used in combination with CPT to identify potential markers of functional Chk1 inhibition, as well as resulting cell cycle progression, using cDNAbased microarrays. Differential expression of several of these putative marker genes was further validated by RT-PCR for use as a medium-throughput assay. In the presence of DNA damage, Chk1 inhibitors altered CPT-dependent effects on the expression of cell cycle and DNA repair genes in a manner consistent with a Chk1-specific mechanism of action. Furthermore, differential expression of selected marker genes, cyclin E2, EGR1, and DDIT3, was dose dependent for Chk1 inhibition. RT-PCR results for these genes following treatment with a panel of Chk1 inhibitors showed a strong correlation between marker gene response and the ability of each compound to abrogate cell cycle arrest in situ following CPT-induced DNA damage. These results demonstrate the utility of global expression analysis to identify surrogate markers, providing an alternative method for rapid compound characterization to support advancement decisions in early drug discovery. (Journal of Biomolecular Screening 2006:792-806) 
INTRODUCTION
C ELL CYCLE CHECKPOINTS are necessary for maintenance of DNA integrity as cells proliferate. In normal cells, DNA damage results in cell cycle arrest at G1, S, or G2 checkpoints, depending on the nature of the damage, to prevent aberrant mitosis while the cell attempts to repair the damage. 1 Although the regulation of cell cycle checkpoints is complex and not fully understood, the G1 and G2/M checkpoints are regulated by the activities of p53 and Chk1, respectively, and the S checkpoint appears to be regulated, in large part, by Chk1 as well. 2, 3 In contrast to normal cells, which have fully functional checkpoints, many cancer cells have lost the p53-dependent G1 checkpoint. Thus, p53-deficient cancer cells are more vulnerable to G2 checkpoint inhibition than normal cells. One strategy for rational design of an anticancer therapy is to exploit the vulnerability of tumor cells lacking functional p53 by combining a conventional cytotoxic agent with a checkpoint inhibitor 4, 5 because these cells have only the Chk1-dependent checkpoints remaining to respond to DNA damage.
Camptothecin (CPT) and its analogs in use clinically, such as irinotecan (CPT-11), are chemotherapeutic agents that induce DNA damage by targeting DNA topoisomerase I. 6 Inhibition of topoisomerase I activity by CPT results in double-strand DNA breaks at replication forks and induction of S or G2/M phase cell cycle arrest 2,6-8 while the cell attempts to repair the damage. If the damage cannot be repaired, apoptosis usually results.
Inhibition of Chk1 can increase the sensitivity of cancer cells to DNA damaging agents such as CPT. One of the targets of the staurosporine analog 7-hydroxystaurosporine (UCN-01) is Chk1. 9 UCN-01 has been shown to abrogate CPT-and SN38 (the active metabolite of CPT-11)-induced S and G2 phase arrest and enhance CPT cytotoxicity in breast carcinoma cell lines with mutant p53. 10, 11 UCN-01 also has been shown to enhance cisplatin-induced cytotoxicity in p53-deficient non-small-cell lung carcinoma cells, in part by releasing cells from cisplatininduced G2 arrest. 12 In addition, UCN-01 has shown antitumor activity in several in vivo xenograft models, including head and neck, breast, and pancreatic carcinomas. [13] [14] [15] Although UCN-01 is effective at increasing the sensitivity of cancer cells to DNA damage, it has other molecular targets in addition to Chk1, including checkpoint-related proteins c-TAK1 and Chk2, 16, 17 as well as PKC, Cdk1, and Cdk2. 18, 19 Therefore, there has been a focus on developing more specific Chk1 inhibitors that could potentiate the cytotoxicity of a DNA damaging agent and increase patient survival while minimizing off-target effects, which might contribute to increased toxicity.
Using a high-throughput in vitro enzyme assay to screen compound libraries, novel benzimidazole quinolinones were identified that inhibit Chk1 activity and tumor cell proliferation. Consistent with the expected mechanism of action (MOA), these novel Chk1 inhibitors were shown to release p53 mut MDA-MB-435 breast carcinoma cells from CPT-induced cell cycle arrest. However, the methodology used to evaluate Chk1 inhibition included FACS-based cell cycle analysis, which was labor intensive, particularly if dose-response studies are required. Consequently, identifying an alternate, more high-throughput approach for selecting active Chk1 inhibitors was desirable. Microarray-based expression analyses are becoming more commonly used to identify potential diagnostic, predictive, and toxicity biomarkers. [20] [21] [22] Therefore, microarray analysis was used to identify putative surrogate markers of Chk1 inhibition, and the markers were further validated by RT-PCR analysis of 14 additional benzimidazole quinolinones. Significantly, changes in expression of the chosen marker genes in response to the panel of Chk1 inhibitors were dose dependent and correlated strongly with the ability of each compound to reverse CPT-induced cell cycle arrest. Such an RT-PCR-based assay has potential applications as a medium-throughput surrogate readout for functional effects of Chk1 inhibition on cell cycle release after DNA damaging chemotherapeutic treatment. This dose dependence of transcriptional responses suggests potential utility for compound selection during lead optimization.
MATERIALS AND METHODS

Chk1 inhibitor assay
Activity of proprietary Chk1 inhibitor compounds was measured using a robotic assay of Chk1-dependent phosphorylation of Cdc25c. The purified kinase domain of Chk1 enzyme (final concentration 1.35 nM) was suspended in 30 mM Tris-HCl (pH 7.5), 10 mM MgCl 2 , 2 mM DTT, 4 mM EGTA, 25 mM glycerol phosphate, 5 mM MnCl 2 , and 0.01% bovine serum albumin (BSA)/phosphate-buffered saline (PBS) with 0.5 µM biotinylated Cdc25c peptide substrate. Chk1 enzyme and biotinylated Cdc25c then were incubated with 1 µM cold adenosine triphosphate (ATP) and 8 nM P 33 ATP at room temperature (RT) for 4 to 5 h, covered. The reaction was stopped by the addition of 50 µM cold ATP and 30 mM EDTA in PBS.
A streptavidin-coated plate was blocked for 1 h with 1% BSA/PBS, the BSA solution was aspirated, and 100 µL enzyme reaction was added to the streptavidin plate and incubated at room temperature for 30 to 40 min, covered. The plate was washed with PBS, 200 µL scintillation fluid was added, and the plate was incubated on a shaker for 20 min or left covered overnight. The plate was read on the TopCount Microplate Scintillation Counter (Packard Instrument Co, Meriden, CT).
Cell cycle release assay
The cell cycle analyses for dose-response determination were performed on the Guava Personal Cell Analysis (PCA) System (Guava Technologies, Inc, Hayward, CA). MDA-MB-435 cells were seeded at 1.5 × 10 5 cells/well in a 24-well, flatbottom plate and were allowed to adhere for 6 h at 37 °C in 5% CO 2 . Cells then were preincubated with 50 nM CPT for 18 h and incubated for an additional 6 h in the presence of a range between 0 and 1000 nM of each experimental compound. The incubation times were optimized for this cell line and these drugs. Similar experiments in different cell types might require adjustment of the incubation times.
Following incubation with experimental compounds, the media were collected, cells were trypsinized, and cells and media were pooled from each well. Cells were centrifuged at 4000 rpm for 5 min to pellet cells, the supernatant was aspirated, and the cell pellet was washed with PBS. Cells were centrifuged again at 4000 rpm for 5 min, the supernatant was removed, and cells were fixed with 0.2 mL ice-cold 75% ethanol, pipetting cells to obtain a single cell suspension. Fixed cells were stored at -20 °C for a minimum of 2 h and a maximum of 1 week.
Cells were removed from -20 °C, centrifuged at 8000 rpm for 5 min, and washed with 100 µL PBS. Cells were resuspended in approximately 60 µL of propidium iodide solution (0.2 mg/mL RNase A, 0.025 mg/mL propidium iodide, 0.1% Triton X-100), transferred to a 1.5-mL screw-cap tube, and incubated in the dark at room temperature for 30 min. Cell cycle analysis was performed on the Guava PCA System using Cytosoft Version 2 software from Guava Technologies (Hayward, CA).
Cell cycle release (CCR) EC 50 values were calculated using the XLfit program in Microsoft Excel. The concentration of compound required to produce an approximate 50% change in the number of cells in S phase (CCR EC 50 ) was based on calculation of the midpoint, where the baseline (A) was the number of cells in the S phase in the presence of CPT alone (0 nM compound), and the maximum change (B) was the number of cells in the S phase in the presence of the highest concentration of experimental compound plus CPT. The calculation of the midpoint was [(A -B)/2] + B and was used in XLfit Model 205 (y = A + ((B -A)/(1 + ((C/x)^D)))) to calculate the CCR EC 50 .
Culture conditions for transcriptional profiling and quantitative RT-PCR marker validation
MDA-MB-435 breast carcinoma cells were maintained in Dulbecco's modified Eagle's medium (DMEM)/Ham's F-12 (Mediatech, Inc, Herndon, VA) supplemented with 10% fetal bovine serum (FBS), 1% sodium pyruvate, nonessential amino acids, L-glutamine, and penicillin/streptomycin. For transcriptional profiling, cells were seeded at 2 × 10 5 cells/mL in 15-cm 2 dishes in OptiMEM I (Invitrogen, Carlsbad, CA) + 4% FBS and were allowed to adhere for 6 h at 37 °C in 5% CO 2 . Cells then were preincubated with 50 nM CPT for 18 h and incubated for an additional 6 h in the presence or absence of 30 nM of each experimental compound. For the marker validation experiment, cells were seeded at 5 × 10 4 cells/well in 96-well flatbottom plates in OptiMEM I + 4% FBS, and treatment conditions were identical to those used for transcriptional profiling. As stated in the cell cycle release methods, incubation times were optimized for this cell line and these drugs.
Culture conditions for quantitative RT-PCR dose-response analyses
For the initial dose-response experiment (with Chk1 inhibitors CHIR-A, CHIR-B, and the negative control CHIR-C) ( Fig. 2) , cells were seeded at 5 × 10 4 cells/well in 96-well flat-bottom plates in OptiMEM I + 4% FBS. Cells were preincubated with 50 nM CPT for 18 h and then incubated with 1, 3, 10, 30, 100, and 300 nM of CHIR-A, CHIR-B, or CHIR-C for 6 h. For the doseresponse study with the expanded profile of compounds ( Fig. 4 , Table 5 ), cells were seeded at 5 × 10 4 cells/well in 96-well flatbottom plates in OptiMEM I + 4% FBS. Cells were preincubated with 50 nM CPT for 18 h and then incubated with 5, 15, 50, 150, 450, and 1000 nM of the experimental compounds for 6 h.
Quantitative RT-PCR (qRT-PCR) EC 50 values were calculated using the XLfit program in Microsoft Excel. The concentration of compound required to produce an approximate 50% change in gene expression (EC 50 ) was based on calculation of the midpoint, where the baseline (A) was the gene expression in the presence of CPT alone (0 nM experimental compound), and the maximum change (B) was the gene expression in the presence of the highest concentration of compound plus CPT. The calculation of the midpoint was [(A -B)/2] + B and was used in XLfit Model 205 (y = A + ((B -A)/(1 + ((C/x)^D)))) to calculate the EC 50 . cDNA microarrays mRNA expression was measured using custom-designed spotted cDNA microarrays. Aluminum-coated glass slides were spotted in duplicate with 4608 cDNA clones (of which 384 are controls) using a Molecular Dynamics Gen III spotter. All clones were sequenced to verify their identity and assigned to 3160 unique transcripts by GenBank accession, representing 2740 unique genes by Locus Link ID. Of these, 953 genes were measured by at least 2 clones, usually with different sequences (for additional detail, refer to Supplemental Materials and Methods).
Transcriptional profiling
RNA was prepared using the RNeasy kit (Qiagen, Inc, Valencia, CA), according to the manufacturer's instructions. First-strand cDNA was synthesized by reverse transcription from 1 µg of poly-A selected mRNA (polyA selection with Oligotex resin, Qiagen, Inc), during which Cy3 or Cy5 fluorescently labeled nucleotides were incorporated. The primer was annealed to the mRNA by mixing 1 µg of mRNA with 2 µL oligo (dT) 25 (Amersham Biosciences, now part of GE Healthcare Bio-Sciences Corp, Piscataway, NJ), 0.14 µg/µL random nonamers (Amersham Biosciences, now part of GE Healthcare Bio-Sciences Corp), 2 µL internal RNA standards, and RNase-free water to a total volume of 21 µL. The mixture was incubated for 12 min at 70 °C and then cooled to room temperature. For the reverse transcription reaction, the annealed mRNA and primer was mixed with 8 µL RT buffer (Gibco Invitrogen Corp, Carlsbad, CA), 4 µL 0.1 M DTT, 2 µL nucleotide mix (2 mM dATP, dGTP, dTTP, and 1 mM dCTP, Amersham Biosciences, now part of GE Healthcare Bio-Sciences Corp), 1 µL RNasin, 2 µL Cy5/Cy3-dCTP (Amersham Biosciences, now part of GE Healthcare Bio-Sciences Corp), and 1200 units of SuperScript II reverse transcriptase (Gibco Invitrogen Corp). The reaction was incubated at 42 °C for 150 min and then placed on ice. To this mixture was added 1 unit RNase H and 1 unit RNase One (in 20 µL 1× RT buffer), and the reaction was incubated for 20 min at 37 °C. Unincorporated nucleotides were removed with the QIAquick PCR purification kit (Qiagen, Inc), according to manufacturer's instructions. This generated enough probe for 4 chips (250 ng cDNA per chip).
RNA expression was always measured and expressed as a ratio between cohybridized pairs of samples, one labeled with Cy3, the other with Cy5. For each pair of samples, dye swapping was performed to control for bias introduced by the fluorescence properties of the dyes. Each pairing of dyes was run in duplicate for a total of 4 spots per ratio.
Microarray chips were prehybridized in prewarmed solution (50% formamide, 5× SSC, 0.2% SDS) for 2 h at 42 °C. Slides were washed in double-distilled water twice and then dried with N 2 gas. To prepare the probes for hybridization, 250 ng of each probe was mixed with 1 µg/µL oligo poly-A80 (prepared at Chiron) and 1 µg/µL C 0 t-1 DNA (Gibco Invitrogen Corp), heat denatured for 2 min at 95 °C, and incubated in a 70 °C water bath for 1 h. Probes were then incubated with 22.5 µL hybridization mix (1 volume Version II buffer [Amersham Biosciences, now part of GE Healthcare Bio-Sciences Corp] and 2 volumes 100% deionized formamide) at 42 °C for 1 h. Finally, pairs of samples were cohybridized onto the prehybridized array slide for 16 h at 42 °C in a box containing prehybridization solution. Following hybridization, slides were washed several times. First, slides were washed in 1× SSC, 0.2% SDS (prewarmed to 55 °C) for 5 min on a shaker. Next, slides were washed twice in 0.1× SSC, 0.2% SDS (prewarmed). Slides were dipped 5 times and then washed 10 min, and the process was repeated in fresh wash solution. Third, slides were dipped 5 times in prewarmed 0.1× SSC twice, using fresh wash solution each time. Finally, slides were dipped 3 times in water, dried with N 2 gas, and stored away from light. The chips were scanned with a Molecular Dynamics Gen III scanner (Amersham Biosciences, now part of GE Healthcare Bio-Sciences Corp).
Data analysis and statistics
Because of the sheer number of gene expression assays performed when measuring a sample with microarrays, statistical analysis of the resulting data presents unique challenges. For an overview of relevant issues and common solutions, see Allison et al. 23 We developed our analysis methods to address many of these issues using standard statistical techniques 24 concurrently with the development of our array platform. Our methods are discussed in much greater detail in the Supplementary Methods; only a brief overview is presented here. Microarray image analysis was performed using ImaGene software (BioDiscovery, El Segundo, CA). For each spot, the median pixel intensity and standard deviation were determined, as well as the spot area, signal area, and local background intensity. For each cDNA clone, the results from 4 spots (2 duplicates per slide, Cy3 and Cy5 labeled) were averaged, and a standard deviation was calculated. A clone was called detected if its signal was at least 5 standard deviations above background. A ratio of expression between the 2 samples and its uncertainty were calculated from the intensities. A global normalization was then applied such that the median ratio observed across all of the cDNA spots was assigned a value of 1. For each ratio, a significance call was assigned: undetected (in both the numerator and denominator), on (detected in the numerator only), off (detected in the denominator only), up or down (significantly overexpressed in the numerator or denominator, respectively, by at least 1.65 standard deviations; p < 0.05), or equal (detected, but ratio not significantly different from 1). A minimum fold change was also calculated as the lower 95% confidence limit on the ratio.
Two biological replicate samples were prepared for each pair of cell treatment conditions. The average ratio was calculated from the replicate ratios weighted by their inverse variances. The uncertainty in the average was estimated from the larger of the error in the weighted mean or the average variance of the replicates. This uncertainty was then used to make a significance call and to calculate the minimum fold change as above.
Quantitative RT-PCR assays
RNA was prepared using the RNeasy kit (Qiagen, Inc), according to manufacturer's instructions, and then 2-step qRT-PCR was done. cDNA was generated by combining 4 µL eluted RNA with the reaction buffer containing MMLV RT 10× buffer (Ambion, Inc, Austin, TX), 10 pmoles oligo dT (Ambion), 10 pmoles random decamers (Ambion), 500 µM each dNTP (Roche Applied Science, Indianapolis, IN), 20 units RNase inhibitor (Ambion), and 50 units of MMLV reverse transcriptase (Ambion). The reaction was incubated for 1 h at 42 °C, and 2 µL of the resulting cDNA solution was then used for the PCR reaction.
Cyclin E2, DDIT3, EGR1, and GAPDH PCR primers and probes were purchased from Assays-on-Demand Gene Expression Kits (Applied Biosystems, Foster City, CA). The PCR reaction was done according to the Assays-on-Demand protocol for a 50-µL reaction, with 22.5 µL from the cDNA preparation used for each PCR reaction. The reaction parameters were as follows: 10-min hold at 95 °C, 45 cycles of 15 sec at 95 °C, 1 min at 60 °C.
RESULTS
Novel Chk1 inhibitor compounds reverse CPT-induced cell cycle arrest
Novel, proprietary Chk1 inhibitor compounds were identified using a cell-free enzyme assay that measured inhibition of phosphorylation of the Chk1 substrate Cdc25c, as described in Materials and Methods. Among the compound series identified were 4-(aminoalklyamino)-3-benzimidazole-quinolinones (ZJ Ni et al., manuscript submitted), similar to compounds CHIR-A, CHIR-B, and CHIR-C shown in Figure 1 . The activities of these compounds were profiled against a number of other kinases, and the compounds were shown to be highly selective against most other kinases tested, including many receptor tyrosine kinases and cyclin-dependent kinases (Table 1) (K Rendahl et al., manuscript submitted). As expected, most Chk1 inhibitors tested that showed potent activity in vitro were able to release CPT-induced cell cycle arrest.
Transcriptional profiling of CPT and Chk1 inhibitors
A microarray-based study was initiated to determine whether transcriptional responses to Chk1 inhibition and CCR could be identified that might provide surrogate markers of relative efficacy of compounds in the series. A further aim was to determine whether such surrogate markers could be converted to a qRT-PCR-based assay capable of indicating relative efficacy of novel compounds, replacing the more labor-intensive cell cycle analysis assay.
To identify gene expression changes specifically correlated with Chk1 inhibitor-dependent CCR following DNA damageinduced arrest, a transcriptional profiling experiment was done as described in Materials and Methods, using a custom cDNA microarray. The experiment was designed to reveal (1) specific transcriptional responses to DNA damage by CPT, (2) specific effects of Chk1 inhibition in the presence of DNA damage (i.e., correlates of CCR), and (3) any nonspecific effects of benzimidazole quinolinones. It is important to note that direct competitive hybridization of cDNA was used in all microarray experiments (i.e., RNA from 2 groups was used to generate differentially labeled cDNA hybridized to a single custom chip). Thus, differential expression across the 2 conditions was measured as a ratio, and absolute mRNA levels in each sample were not determined.
Three novel compounds ( Fig. 1) were selected for initial study. Two of the compounds, referred to as CHIR-A and CHIR-B, are potent inhibitors of Chk1 kinase activity in vitro with IC 50 s of 0.3 nM and 0.2 nM, respectively. The third compound, included as a negative control (referred to as CHIR-C), has a much higher IC 50 against Chk1, 1.7 µM. As shown in Figure 1 , this less active compound is nearly structurally identical to CHIR-A, with only a single Cl substituent difference between the two. CHIR-A and CHIR-B were able to release cells from CPT-induced cell cycle arrest at the concentration used in the microarray study (30 nM), whereas the less active CHIR-C was unable to cause CCR at concentrations up to 1 µM, thus serving as a control for nonspecific effects of the chemical series.
The transcriptional response to DNA damage associated with CPT treatment has been characterized previously. 25 Expression profiling in the HCT116 colon cancer cell line 26, 27 provides a point of comparison for studies in the breast cancer 
The activities of CHIR-A, CHIR-B, and CHIR-C were profiled against Chk1 and a number of other kinases. The Chk1 activities are listed in nM, with the fold difference against the other profiled kinases shown. ND, no determined. line chosen for our experiments, MDA-MB-435. To identify genes differentially expressed in MDA-MB-435 cells in response to CPT-induced DNA damage, RNA from cells treated with CPT alone (50 nM) and RNA from vehicle-treated cells were compared by direct competitive hybridization. To identify potential surrogate markers of Chk1 inhibition, cells were treated with CPT ±30 nM CHIR-A or CHIR-B, and cDNA from these cells was compared by competitive cDNA hybridization to that in cells treated with CPT alone.
To identify nonspecific effects of the benzimidazole quinolinone scaffold unrelated to Chk1 inhibition, several methods were used. First, biochemical activity of the potent Chk1 inhibitors was tested against a panel of kinases. Results demonstrated >20× selectivity for Chk1 compared to other kinases, with the exception of Rsk2 ( Table 1) . Second, transcriptional responses to the control compound (CHIR-C) plus CPT were compared to the effects of CPT alone. This comparison should identify off-target effects associated with this class of small molecules apart from any effect on Chk1 kinase activity. Finally, active Chk1 inhibitors are not expected to have a pronounced effect on transcription in the absence of DNA damage and activation of the ATR pathway because activation of the pathway is required for Chk1 kinase activation. Therefore, any transcriptional changes in response to the potent Chk1 inhibitor compounds alone (CHIR-A, CHIR-B) in cells not exposed to DNA damage (e.g., with CPT) also were considered to be unrelated to specific inhibition of Chk1 activity.
CPT-induced gene expression changes are consistent with known mechanism of action
It has been shown previously that CPT treatment and the resulting DNA damage response alter transcription of multiple genes involved in cell cycle regulation, apoptosis, and DNA repair in HCT116 cells. 26, 27 These studies demonstrate that specific gene expression changes obtained upon CPT treatment are dependent on concentration, time, and p53 status. When we treated MDA-MB-435 cells with CPT for 24 h, the observed changes in gene expression were not identical to those previously reported in HCT116 cells but were similarly consistent with CPT's known MOA and included changes in expression of cell cycle, apoptosis-associated, and stress response genes. These differences were not unexpected because MDA-MB-435 cells and HCT116 cells have different p53 status (HCT116 cells are p53 + and MDA-MB-435 cells are p53 -), and the length of CPT treatment was different between the published work and our studies. Expression of 93 unique genes (some represented by multiple array probes) was significantly altered, with ≥1.5-fold minimum fold change (min fold change), where "min fold change" is defined as the minimum change in expression that meets the 95% confidence threshold (p ≤ 0.05). (See
Materials and Methods and Supplementary Material for details of algorithms.)
CPT treatment resulted in differential expression (≥1.5-fold) of several classes of genes, including some involved in apoptosis, DNA damage and repair, cell cycle, extracellular matrix maintenance, transcriptional regulation, and signal transduction. The exact relationship between changes in transcription of many of these differentially regulated genes and CPT-induced DNA damage response, cell cycle arrest, and apoptosis has not been described. However, the subset of these genes with known roles in these processes is shown in Table 2 . These MOArelated changes included differential expression of apoptosisregulating genes such as BNIP3 and FAF1; induction of DNA repair genes, including DDIT3 and GADD45B; and differential expression of a number of cell cycle regulatory genes, including cyclin E1, cyclin E2, and p21 Cip1/Waf1 . (The complete data set describing all genes differentially expressed ≥1.5-fold [95% confidence interval] in CPT versus untreated cells is listed in Supplementary Table 1 . See http://jbx.sagepub.com/cgi/content/ full/11/7/792/DC1.)
Chk1 inhibitors alter gene expression in CPT-treated cells
Consistent with their similar structures and activities against Chk1, the transcriptional responses to CHIR-A and CHIR-B compounds in the presence of CPT overlapped significantly. Specifically, 33 genes were differentially expressed (≥1.5 min fold change) in response to both CHIR-A and CHIR-B treatments following preincubation with CPT. An additional 18 and 10 genes, respectively, were differentially expressed in response to only CHIR-A or CHIR-B (plus CPT) compared to CPT alone. (The complete data set of genes differentially expressed ≥1.5-fold is available as Supplementary Table 2 . See http://jbx.sagepub.com/cgi/content/full/11/7/792/DC1.) Treatment with CHIR-A or CHIR-B following exposure to CPT resulted in differential expression of similar classes of genes as CPT alone, including genes involved in apoptosis, DNA damage response and repair, cell cycle, extracellular matrix, transcriptional regulation, and signaling. In the presence of CPT-induced DNA damage, the Chk1 inhibitors reversed the CPT-dependent effect on transcription of some genes and further amplified the CPT-dependent effect on other genes. A subset of these genes associated with MOA of CPT and Chk1 inhibition is shown in Table 3 and include a number of apoptosis-related, cell cycle-related, and DNA repair-related genes. The genes differentially expressed in response to only CHIR-A or CHIR-B (plus CPT) compared to CPT alone could be a result of the somewhat different selectivity profile of these related compounds (Table 1) . However, as can be seen in Supplementary Table 2 , the level of differential expression for those genes unique to CHIR-A or CHIR-B was very close to the significance cutoff of 1.5 min fold change. Therefore, an Surrogate Markers of Chk1 Inhibitor-Induced Cell Cycle Release alternate explanation could be that the differential expression profiles were related to the in situ potencies of the 2 compounds.
Few off-target effects of Chk1 inhibitors alone or a less active control
To identify possible nonspecific, off-target effects of this class of small-molecule inhibitors on cell physiology, the transcriptional effects of (1) the structurally related but less active control compound CHIR-C plus CPT versus CPT alone and (2) the active Chk1 inhibitors in the absence of DNA damaging agent versus untreated cells were analyzed. There were few differentially expressed genes (≥1.5 min fold change) in these comparisons: no genes were differentially expressed in response to the control CHIR-C plus CPT compared to CPT alone, and only 12 genes were differentially expressed in response to CHIR-C alone compared to untreated cells. With CHIR-A or CHIR-B alone, 1 and 21 genes were differentially expressed compared to untreated cells, respectively. Thus, there were few nonspecific transcriptional effects of these compounds. In addition, in contrast to the mechanism-related genes differentially expressed in response to Chk1 inhibitors in the presence of CPT, none of the genes differentially expressed in response to Chk1 inhibitors alone or to the control CHIR-C had a known functional link to the cell cycle or other aspects of Chk1's MOA (data not shown). Although there are reports of active DNA damage checkpoint pathways in some cancer cells compared to normal cells, 28, 29 the small response to the Chk1 inhibitors in the absence of CPT indicates that these cells likely do not have fully active Chk1 in the absence of the CPT-induced DNA damage. Thus, at 30 nM, the vast majority of transcriptional effects induced by CHIR-A and CHIR-B in the presence of DNA damage appeared to be the specific result of Chk1 inhibition.
Differential expression of candidate markers of Chk1 inhibition confirmed by quantitative RT-PCR
Potential surrogate markers of Chk1 inhibition were selected from the list of genes in Table 3 for further validation on the basis of several criteria. Markers were chosen that (1) were CPT treatment resulted in differential expression (≥1.5-fold) of several classes of genes, including some involved in apoptosis, DNA damage and repair, cell cycle, extracellular matrix maintenance, transcriptional regulation, and signal transduction. The subset of these genes with known roles in CPT-induced DNA damage response, cell cycle arrest, and apoptosis is shown. The "min fold change" represents the minimum change in expression that meets the 95% confidence threshold (p ≤ 0.05). The direction of change (increased or decreased expression, relative to untreated cells) is represented by the arrow in the min fold change column. The complete data set describing all genes differentially expressed ≥1.5-fold (95% confidence interval) in CPT versus untreated cells is listed in Supplementary Table 1 . MOA, mechanism of action; CPT, camptothecin; ADP, adenosine diphosphate.
thought to be relevant to the Chk1 MOA, (2) had greater than 2-fold differential expression, and (3) were also differentially expressed in a similar preliminary microarray experiment (data not shown). The genes selected on this basis for further investigation were cyclin E2 (CCNE2), DDIT3, and EGR1.
The transcriptional effect of Chk1 inhibitor treatment on the selected candidate markers was first confirmed by qRT-PCR using the same mRNA used to generate cDNA for the transcriptional profiling. As shown in Table 4 (confirmatory qRT-PCR data), the observed expression changes in response to Table 2 and includes a number of apoptosis-related, cell cycle-related, and DNA repair-related genes. The "min fold change" represents the minimum change in expression that meets the 95% confidence threshold (p ≤ 0.05). The direction of change (increased or decreased expression, relative to cells treated with CPT alone) is represented by the arrow in the min fold change column. The complete data set describing all genes differentially expressed ≥1.5-fold (95% confidence interval) in CPT versus CPT + CHIR-A/CHIR-B is listed in Supplementary Table 2 . Gene symbols with an * are genes that are also differentially expressed in response to CPT alone ( Table 1) . MOA, mechanism of action; CPT, camptothecin; ADP, adenosine diphosphate; N/S, nonsignificant differential expression.
CPT plus Chk1 inhibitors compared to CPT alone were confirmed for the 3 markers retested.
To further confirm the reproducibility of the array results, the tissue culture experiment was repeated in a 96-well plate format, under the same treatment conditions used originally for transcriptional profiling. Following incubation with CPT, the Chk1 inhibitor compounds CHIR-A and CHIR-B, or the control compound CHIR-C, RNA was harvested and qRT-PCR was performed, as described in Materials and Methods. As summarized in Table 4 (reproducibility qRT-PCR data), the observed expression changes in response to CPT plus Chk1 inhibitors compared to CPT alone were similar to those observed in both the initial array results and the confirmatory qRT-PCR for all 3 candidate markers.
Chk1 inhibitors have a dose-dependent effect on surrogate marker expression
To determine whether the transcriptional responses to Chk1 inhibition might provide information about the relative efficacy of compounds, we next investigated the effect of different doses of Chk1 inhibitor on marker gene expression using the 96-well format and qRT-PCR. The results of a dose-response study with CHIR-A, CHIR-B, and CHIR-C are shown in Figure 2 . All 3 validated marker genes showed a dose-dependent response to the active compounds (CHIR-A and CHIR-B) in the presence of DNA damage, whereas the less active compound CHIR-C (also in the presence of CPT) had no effect on gene expression. Consistent with the initial qRT-PCR results (Table 4) , CHIR-A appeared to have a slightly more potent effect on expression of all 3 genes than CHIR-B.
Chk1 inhibitors have a dose-dependent effect on cell cycle release
The ability of an inhibitor to release MDA-MB-435 cells from CPT-induced cell cycle arrest is a direct in situ measure of functional Chk1 inhibition. Therefore, CCR data had been generated previously for the majority of the novel Chk1 compounds. However, these initial cell cycle profiles were performed under different experimental conditions than the conditions of the transcriptional profiling experiment (different CPT concentration and Chk1 inhibitor incubation time), and the labor-intensiveness of the assay did not provide the throughput necessary for a dose-response analysis of effects on cell cycle. In an effort to examine whether expression of these candidate marker genes could be used to categorize compounds according to their potency against Chk1 in situ, it was desirable to have dose-response analyses of CCR for eventual comparison and correlation with the transcriptional regulation of the candidate markers. Therefore, a propidium iodide-based CCR assay was performed at multiple concentrations on a subset of the compounds, using the conditions of the transcriptional profiling and qRT-PCR experiments (see Materials and Methods for details). In addition to CHIR-A, CHIR-B, and CHIR-C, 13 CCR-positive Chk1 inhibitors and 1 CCR-negative, structurally related compound were selected for this expanded doseresponse study, based on their observed activities in the original cell cycle profiling experiments.
The dose-dependent ability of the CCR-positive Chk1 inhibitor compounds to release cells from the CPT-induced arrest and to progress through the cell cycle could be observed by following the decrease of cells in the S phase and the corresponding increase in cells in the G2/M phase as the concentration of the inhibitor increased. No changes in the fraction of cells in S or G2/M were observed when cells were treated with compounds lacking Chk1 activity. The cell cycle profiles generated with 3 representative experimental compounds are shown in Figure 3 .
Compared to CPT alone, CCR-positive compounds caused a significant decrease in the number of cells in the S phase, so that at the highest concentrations of compounds, the number of cells in the S phase was close to the background level for the assay. Consistent with this compound-dependent release from arrest in the S phase, there was a concomitant increase in the number of cells in the G2/M phase with increased compound 
Expression of markers of Chk1 inhibition was evaluated by quantitative RT-PCR (qRT-PCR). The experiments were done in duplicate, and the expression of each gene was normalized to the expression of the housekeeping gene GAPDH. The mean normalized expression is reported for each gene. All differential expression results are ratios of the CPT + Chk1 inhibitor compared to CPT alone, with the direction of change in response to the Chk1 inhibitor indicated by the arrow. For the microarray experiment, the average min fold change is reported, with the direction of change indicated by the arrow. For the qRT-PCR experiments, the absolute differential expression is reported, based on the normalized gene expression, with direction of change indicated by the arrow. The confirmatory qRT-PCR was done using the same mRNA used to generate the cDNA for transcriptional profiling. The reproducibility qRT-PCR was done in a 96-well plate format. CPT, camptothecin.
concentration. This is consistent with the original cell cycle observations, showing a Chk1 inhibitor-dependent release from CPT-induced arrest. This cell cycle analysis demonstrated that the CCR-positive Chk1 inhibitors released cells from CPTinduced arrest in a dose-responsive manner, and the concentration of compound required to produce an approximate 50% change in the number of cells in the S phase was calculated and termed the EC 50 s for cell cycle release (CCR EC 50 ). As expected, EC 50 values were larger than the IC 50 values generated in the cell-free enzyme assay due to the additional interaction of the compounds with the cellular environment. However, the rank orders of CCR EC 50 and IC 50 values were nearly identical for those compounds put through this CCR assay. Values for all compounds analyzed by this method are shown in Table 5 .
Marker expression may be used to differentiate relative potencies of Chk1 inhibitors
To investigate whether expression of the candidate surrogate marker genes could be used to categorize compounds according to their potency against Chk1 in situ, cells were treated with the expanded panel of compounds, and expression of CCNE2, EGR1, and DDIT3 was analyzed by qRT-PCR. The concentration of compound required to produce an approximate 50% change in gene expression relative to the maximum and minimum expression levels measured was defined as the EC 50 of expression for that compound and marker gene combination. An approximate EC 50 was generated from these dose-response studies to provide single points for eventual comparison and correlation with the compound-dependent release from cell cycle arrest. Across the set of compounds, Chk1 IC 50 values from the cell-free kinase assay varied widely; therefore, an expanded range of concentrations was used in these experiments to determine expression EC 50 s, compared to those in the initial dose-response study (Fig. 2) . As with the previous experiments, cells were treated with CPT for 18 h and then treated with a range of concentrations of the experimental compounds for an additional 6 h, and qRT-PCR was performed for the 3 candidate marker genes. The results for a subset of compounds are shown in Figure 4 and are representative of the dose responsiveness of all 17 compounds tested.
As observed with the original test compounds (Fig. 2) , all 3 marker genes showed a dose-dependent response to the CCRpositive Chk1 inhibitors and no response to the CCR-negative compounds that lack activity against Chk1. Unexpectedly, the effects of 2 compounds on expression of DDIT3 showed a pattern not explicable by Chk1 inhibition alone (Fig. 4C , compounds CHIR-D, CHIR-I). However, biochemical data from the kinase selectivity panel and expression data with other kinase inhibitors (data not shown) indicated that at high concentrations, both of these compounds inhibited an additional kinase that was not inhibited by the other compounds, and this might account for the unusual profiles. The response to the CCR-positive and CCR-negative compounds suggested that the dose-dependent expression profiles of the marker genes could be used to differentiate relative potencies of the compounds. Thus, marker gene expression EC 50 s were generated for the initial 3 compounds as well as for the additional 14 compounds ( Table 6 ). Although exact rank ordering of compound EC 50 varied depending on the marker gene in question, general trends were evident and negative compounds clearly distinguishable.
Surrogate marker expression predicts functional cell cycle effect in situ
To determine how well the selected markers of Chk1 inhibition correlated with the direct functional in situ CCR assay, correlation analyses were done using the marker gene expression EC 50 s generated from the qRT-PCR dose-response experiments ( Table 6 ) and the CCR EC 50 s ( Table 5) . Changes in expression of each of the marker genes for Chk1 inhibition proved to be highly correlated with cell cycle release (Figure 5) . Spearman rank correlation coefficients were +0.950, +0.933, and +0.767 for CCNE2, EGR1, and DDIT3, respectively. Spearman rank correlation was chosen for the initial analysis because this nonparametric test allowed the inclusion of the one data point that was outside the detection range of the assay (the negative control compound CHIR-C). Pearson correlations coefficients were also calculated and showed excellent correlation between CCR EC 50 s and the marker gene EC 50 s with correlation coefficients 
DISCUSSION AND CONCLUSIONS
Inhibitors of Chk1 have previously been shown to be active in mouse xenograft models. Here novel Chk1 inhibitors were used in combination with CPT, a well-characterized cancer therapeutic agent that causes DNA damage and cell cycle arrest. Using microarray analysis, candidate surrogate markers of Chk1 inhibition following DNA damage by CPT were identified in p53 mut MDA-MB-435 breast carcinoma cells. Three genes showing relatively large changes in expression and a functional relation to predicted Chk1 MOA were chosen for further study. Differential expression of these marker genes in response to Chk1 inhibition was confirmed by qRT-PCR for a few compounds initially and then extended to a larger set of structurally related compounds. Rather than being an all-ornothing response, changes in marker expression were found to be dose dependent for all 3 markers. The observed effect on marker transcription could be used to calculate a relative expression EC 50 against each gene, allowing comparison of compounds. Although exact expression EC 50 values were somewhat dependent on the identity of the marker gene, EC 50 s for all 3 markers showed good correlation to a functional readout of Chk1 inhibition-namely, release from CPT-induced cell cycle arrest. These results suggest the potential of array-based chemogenomics to identify surrogate markers for functional readouts. In particular, qRT-PCR of genes characterized here as markers of Chk1 inhibition could be useful to speed compound characterization during lead optimization, replacing the more time-consuming cell cycle analyses.
As described above, the 3 markers of Chk1 inhibition selected for further validation were CCNE2, DDIT3, and EGR1. All showed greater than 2-fold differential expression and have functions with possible relevance to the Chk1 MOA. Although changes above 1.5 min fold change were considered statistically significant in the microarray analysis, a 2-fold cutoff was chosen for selection of markers for further validation based on preliminary experiments, indicating that a minimum of 2-fold differential expression was necessary for development of a reproducible qRT-PCR-based assay. CCNE2 is a G1 cyclin regulated both transcriptionally and posttranslationally, 30, 31 with CCNE2 RNA levels fluctuating throughout the cell cycle and being maximal at the G1/S boundary. 31 CCNE2 associates with Cdk2 and is necessary for the G1 to S phase transition. 32 It has been demonstrated that Chk1 can inactivate the phosphatase Cdc25A in response to DNA damage, resulting in inactivation of Cyclin E-Cdk2 kinase and cell cycle arrest. 33, 34 In response to DNA damage induced by CPT, CCNE2 is upregulated about 2-fold relative to mRNA levels in untreated cells. Upon treatment with both CPT and a potent Chk1 inhibitor, CCNE2 expression was downregulated relative to cells treated with CPT alone. This reduced CCNE2 expression, even in the presence of DNA damage, appears consistent with the absence of arrest and accumulation in the S phase seen when Chk1 is blocked.
DDIT3 is a transcription factor that has been shown to be actively involved in the induction of cell cycle arrest and apoptosis in response to cellular stress. 35 Although there is no direct connection documented between DDIT3 and Chk1, induction of DDIT3 expression in response to Chk1 inhibition in the presence of DNA damage may reflect a proapoptotic signal to the cell.
Finally, EGR1 is a transcription factor with tissue-specific regulation. In breast tumors, it has been shown to have tumor suppressor properties and to play a role in induction of PTEN. 36 Furthermore, Egr-1 has been shown to directly regulate expression of p21 Cip1 . 37 Although a direct link between Chk1 and Egr-1 has not been identified, Egr-1 induction following Chk1 inhibition in the presence of CPT-induced DNA damage is consistent with the growth inhibitory effects of CPT + Chk1 inhibitors.
Microarray-based studies are an appealing approach to surrogate marker discovery, providing information on regulation of thousands of genes at once. However, there are many factors to consider in using this technology to identify candidate surrogate markers for drug discovery. Small-molecule inhibitors, especially during lead optimization, are not always highly specific for a single enzyme, which could result in transcriptional changes in the expression of selected markers due to effects on other targets, particularly when used at concentrations many times the IC 50 for the target of interest. For example, the effects of 2 compounds on the expression of DDIT3 showed a pattern not explicable by Chk1 inhibition alone ( Fig. 4C, compounds D, I) .
The potential specificity complication can be addressed by including appropriate controls of a similar chemical structure in the initial microarray experiment, as well as by directly profiling the biochemical activities of test compounds. Based on the information from the kinase selectivity profiling done for the active compounds in this study, we were able to select appropriate control compounds. In fact, biochemical data from the kinase selectivity panel and expression data with other kinase inhibitors provided an explanation for the unusual DDIT3 profile observed in response to CHIR-D and CHIR-I. At high concentrations, these compounds inhibit additional kinases, and this may account for the unusual profiles. Furthermore, although the active compounds were highly selective for Chk1, they did have some activity against Rsk2 as well. However, the CCRpositive compound CHIR-K and the negative control CHIR-C had similar Rsk2 activity, indicating that Rsk2 activity could not explain the results we are reporting.
In addition to selecting appropriate controls to address the issue of specificity, another technique to increase the probable relevance of surrogate markers is to select those genes with a known or suspected link to the desired MOA. It seems probable this further filter should result in marker expression better correlated to the function outcome, as demonstrated in these studies of Chk1 inhibitors.
Although the use of a direct functional assay is desirable for the evaluation of novel, targeted small-molecule inhibitors, it is not always feasible or cost-effective. In the case of Chk1 inhibitors, the original CCR assay, although valuable as a direct measure of Chk1 inhibition, was labor intensive, particularly if dose-response analyses were required. Identification and validation of markers provided a medium-to high-throughput qRT-PCR alternative that was highly predictive of relative functional effects of candidate inhibitors. It remains to be determined if these markers are fairly universal markers of Chk1 inhibition or are specific to this series of compounds. Testing of these markers in other cell lines and for other chemical scaffolds could extend their utility. Development of protein-based assays based on expression data could further strengthen the validity of markers and might offer an alternative medium-to highthroughput screening assay.
Although the exact link between these transcriptional events and the functional readout has not been established, the two are likely driven by a similar constellation of biochemical events. Differential expression of CCNE2, DDIT3, and EGR1 was highly correlated with the efficacy of this series of Chk1 inhibitors in the CCR assay. The relationship between transcriptional effects on these surrogate markers and cell cycle progression may be indirect, and future work will more directly address the causative relationship between cell cycle progression and regulation of these genes at the protein level. However, transcriptional regulation of these genes appears to be predictive of the function outcome, making them useful surrogate markers of compound efficacy in situ.
As experimental Chk1 inhibitors advance into in vivo models and eventually into clinical trials, there will be an ongoing need for markers that are accurate correlates of mechanistic specificity. As Chk1 inhibitors have demonstrated ability to abrogate both S and G2 arrest caused by a variety of clinically relevant DNA damaging agents (doxorubicin, CPT analogs, cisplatin), future experiments will include determining if these surrogate markers could be useful with Chk1 inhibitors combined with DNA damaging agents other than CPT and other topoisomerase inhibitors. In addition, it remains an open question whether surrogate markers correlated with efficacy identified in vitro in a given cell line will have predictive utility across species and tissues. This question can only be answered empirically. However, our prediction is that the gene expression changes most closely tied to the MOA and relevant pathways hold greatest promise for translation across the drug discovery pipeline.
